| Texto completo | |
| Autor(es): |
Goncalves da Silva, Patricia Benites
;
Rodini, Carolina Oliveira
;
Kaid, Carolini
;
Nakahata, Adriana Miti
;
Leite Pereira, Marcia Cristina
;
Matushita, Hamilton
;
da Costa, Silvia Souza
;
Okamoto, Oswaldo Keith
Número total de Autores: 8
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Cytotechnology; v. 68, n. 4, p. 1545-1560, AUG 2016. |
| Citações Web of Science: | 2 |
| Resumo | |
Medulloblastoma is a highly aggressive brain tumor and one of the leading causes of morbidity and mortality related to childhood cancer. These tumors display differential ability to metastasize and respond to treatment, which reflects their high degree of heterogeneity at the genetic and molecular levels. Such heterogeneity of medulloblastoma brings an additional challenge to the understanding of its physiopathology and impacts the development of new therapeutic strategies. This translational effort has been the focus of most pre-clinical studies which invariably employ experimental models using human tumor cell lines. Nonetheless, compared to other cancers, relatively few cell lines of human medulloblastoma are available in central repositories, partly due to the rarity of these tumors and to the intrinsic difficulties in establishing continuous cell lines from pediatric brain tumors. Here, we report the establishment of a new human medulloblastoma cell line which, in comparison with the commonly used and well-established cell line Daoy, is characterized by enhanced proliferation and invasion capabilities, stem cell properties, increased chemoresistance, tumorigenicity in an orthotopic metastatic model, replication of original medulloblastoma behavior in vivo, strong chromosome structural instability and deregulation of genes involved in neural development. These features are advantageous for designing biologically relevant experimental models in clinically oriented studies, making this novel cell line, named USP-13-Med, instrumental for the study of medulloblastoma biology and treatment. (AU) | |
| Processo FAPESP: | 10/52686-5 - Fator de transcrição E2F2 e expressão de proto-oncogenes em células-tronco embrionárias humanas |
| Beneficiário: | Oswaldo Keith Okamoto |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 13/08028-1 - CEGH-CEL - Centro de Estudos do Genoma Humano e de Células-Tronco |
| Beneficiário: | Mayana Zatz |
| Modalidade de apoio: | Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs |